BANTHINE
LOE ApproachingNDAORALTABLET
Approved
Jul 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BANTHINE is an oral tablet small molecule approved in 1951 by Takeda with an unknown mechanism of action and indication profile. The drug's precise therapeutic use cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with minimal Part D visibility suggests a legacy franchise with contracted commercial infrastructure and limited growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate a stable, minimal-staffing operation focused on maintenance and profit extraction rather than growth. Careers on this product offer limited advancement opportunity and are best suited for execution-focused professionals managing mature asset runoff.
Brand ManagerField Sales Representative
Worked on BANTHINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.